Select therapeutic use:

Benign prostatic hyperplasia/urinary retention:

Indications for: CARDURA

Benign prostatic hyperplasia (BPH).

Adult Dosage:

Initially 1mg once daily; may double dose every 1–2 weeks; max 8mg/day.

Children Dosage:

Not applicable.

CARDURA Warnings/Precautions:

Severe hepatic impairment: not recommended. Monitor blood pressure and for orthostatic hypotension initially and if dose increased. Syncope. Cataract surgery (intraoperative floppy iris syndrome possible). Exclude prostate cancer.

CARDURA Classification:

Alpha-1 blocker.

Adverse Reactions:

Dizziness, fatigue, hypotension, edema, dyspnea; rare: priapism.

Metabolism:

Hepatic (O-demethylation, hydroxylation).

Drug Elimination:

Fecal (63%); urine (9%). Half-life: ~22hrs.

How Supplied:

Tabs—100

Hypertension:

Indications for: CARDURA

Hypertension.

Adult Dosage:

Initially 1 mg once daily. Titrate gradually (based on standing BP at 2–6 hours and 24 hours post-dose) at 2-week intervals if needed; max 16 mg/day.

Children Dosage:

Not established.

CARDURA Warnings/Precautions:

Severe hepatic impairment: not recommended. Monitor for orthostatic hypotension initially and if dose increased. Cataract surgery (intraoperative floppy iris syndrome possible). Pregnancy (Cat.C). Nursing mothers.

CARDURA Classification:

Alpha-1 blocker.

CARDURA Interactions:

Caution when adding other antihypertensives.

Adverse Reactions:

Syncope (esp. 1st dose and with increased doses), dizziness, somnolence, fatigue/malaise, edema, rhinitis, abnormal vision, tinnitus, epistaxis, orthostatic hypotension, sexual dysfunction, polyuria, urinary incontinence, ataxia, leukopenia, neutropenia, arrhythmia; rare: priapism.

Metabolism:

Hepatic (O-demethylation, hydroxylation).

Drug Elimination:

Fecal (63%); urine (9%). Half-life: ~22hrs.

How Supplied:

Tabs—100